---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-142816"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T02:40:51.511307+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports high remission rates with ziftomenib in newly diagnosed AML trial

## Summary
- 92% CRc (93% NPM1-m, 89% KMT2A-r) among 71 evaluable patients in KOMET-007 trial.
- 80% complete remission (84% NPM1-m, 74% KMT2A-r); 71% CR-MRD negativity for NPM1-m.
- Median time to MRD negativity 4.7 weeks (NPM1-m) and 4.4 weeks (KMT2A-r).
- Safety consistent with prior data; no QTc prolongation or additive myelosuppression at 600 mg.
- Phase 3 KOMET-017 studies expected to start in H2 2025.

## SEC filing metadata
- accession: 0001193125-25-142816
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/0001193125-25-142816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/d939526d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-142816
- JSON: https://secwatch.observer/filing/0001193125-25-142816.json
- Plain text: https://secwatch.observer/filing/0001193125-25-142816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.